Sponsors

Lead Sponsor

Centre Jean Perrin

OBJECTIVES: Primary * Evaluate the effect of first-line chemotherapy on expression of hormone receptors and biomarkers in women with metastatic breast cancer. Secondary * Assess changes in HER1 and HER2 expression during treatment. OUTLINE: This is a multicenter study. Patients receive 6-9 courses of front-line chemotherapy according to the investigator. Patients with estrogen receptor- and/or progesterone receptor-positive disease receive hormone therapy. Patients undergo biopsy prior to and after completion of chemotherapy for examination of hormone receptors and HER1 and HER2 expression. After completion of study treatment, patients are followed every 6 months for 5 years.

Related studies

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

RECRUITINGPhase 1

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

View all related studies →

Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Trial snapshot

Condition

Locations shown

For caregivers